Merck expands biotech production capacity in Spain

Extension of manufacturing plant will help meet worldwide demand for fertility and growth hormone disorder treatments.

“The demand for our core portfolio of medicines keeps increasing worldwide,” said Simon Sturge, Chief Operating Officer of the biopharma business of Merck. “The expansion in Tres Cantos is part of our continuous commitment to deliver high quality medicines at the right time to our patients.”

“We are continuously investing in our manufacturing network to maintain state-of-the-art industry level and adapt its capacity to patient needs for our medicines,” added Thierry Hulot, Head of Global Manufacturing and Supply for the biopharma business of Merck. “We are very pleased to have completed the expansion of our Tres Cantos biotech manufacturing facility which plays a leading role in our manufacturing network and exemplifies our culture of safety at work, quality and service.”

The €15 million investment, which was made during the 2014-2016 period, adds 900 m2 of biotech production space and a two-floor office building, bringing the total constructed area of the Tres Cantos site to 8,000 m2. The facility complies with the highest international cGMP quality standards. It also observes the highest international standards in terms environment, health and safety. It is certified by ISO 14001 environmental management and safety by OHSAS 18001. The site employs 170 highly qualified professionals.